Systematic erythalamus (SLE) is a self-immunological disease in which immunosuppressants play an important role. The following are some of the relevant points of the systematic selection of their own immunosuppressants:
Considering disease activity and severity
Lightly active and less dirty: If the patient has a relatively light condition, only the symptoms of pain, mild rashes, etc., and when the disease activity rate is lower, priority is given to relatively small side-effects of immunosuppressants, such as hydroxin. Not only does hydroxychloroquine have immunosuppressive effects, but it also has some control over skin damage, light sensitivity, etc., but its long-term use is relatively safe and its adverse effects on important organs, such as the eyes, are controlled under regulatory monitoring.
Patients with light blood systems, such as light white cells and small platelets, may also try to use drugs such as cyclothylene, which has some therapeutic effect on improving blood cell reduction by immunomediate, while avoiding the use of more powerful drugs with higher risk of side effects.
Moderate to severe activity or multiple organs are burdened: when patients suffer from kidney stress, such as lupus renal disease, especially disease type, or when there are major organs of the nervous system, such as stress, heart and lung damage, and the disease is in a medium-heavy activity, more effective immunosuppressants are often required. For example, cytophenate (MMF) is one of the most common drugs currently used to treat lupus nephritis, which effectively inhibits immune responses, reduces the deposition of immunocomposers in areas such as kidneys, improves kidney function, reduces protein urine, etc., and has less of a side effect on drugs such as cyclophosphate, which inhibits the gland.
TCP is also a commonly used powerful immunosuppressant and, in the case of serious and fast-moving systemic erythroacne, especially in cases of severe kidney and life-threatening neurological disorders, is subject to intravenous shock therapy, which can control progress more quickly, but as it can lead to more severe side effects such as bone marrow inhibition, hemorrhagic bladderitis, and gland inhibition, follow-up is required to monitor indicators closely and to implement appropriate protective measures.
Assessing individual tolerance and adverse response risks
Age factor: For young women with reproductive needs, the use of immunosuppressants that are more toxic to the gland, such as ovarian function loss, confinement and even infertility as a result of cyclophosphate use, should be avoided as much as possible, so as to give priority to drugs that have a relatively low impact on the reproductive function, such as cocoproteate and sulphate, if medical conditions permit. In the case of elderly patients, the metabolic capacity of the drug may be reduced as a result of a decline in body function, the risk of an increase in adverse reactions due to the accumulation of the drug in the body is taken into account in the selection of immunosuppressants, the dose of the drug may need to be adjusted as appropriate, and indicators such as haematoma, liver and kidney function are monitored more carefully in order to prevent severe bone marrow inhibition, liver damage, etc.
Basic disease situation: If the patient has a combination of liver diseases, such as hepatitis B, hepatitis C infection or hepatic insufficiency, special care is required in the use of drugs that may increase the liver burden and cause hepatic damage, such as aminophosphate and cyclophosphamine, where necessary, to select drugs that have a small liver impact, such as fluoromett, which is relatively less toxic to the liver than at a reasonable dose, but whose use still requires close monitoring.
For those who combine chronic diseases such as hypertension and diabetes, the use of a combination of sugar cortex hormonal combination immunosuppressants takes into account that the drug may further affect blood pressure, blood sugar control, and the choice of immunosuppressants avoids, to the extent possible, those drugs that exacerbate metabolic disorders, such as cyclic accumulin, which may cause adverse effects such as increased blood pressure and increased blood sugar, which require closer monitoring of blood pressure, blood sugar and adjustment of pressure and sugar reduction programmes.
Considering the interaction of drugs
Many systematic erythalamus patients need to take multiple drugs at the same time, such as high blood pressure, sugar and osteoporosis. If other drugs being taken interact with immunosuppressants, they may affect the efficacy or increase the risk of adverse effects. For example, when cyclists are used in combination with some calcium ion stressants (e.g. nitroplates), they may increase blood concentrations of cyclists and increase the probability of adverse effects such as renal toxicity, so that the choice of immunosuppressants takes a comprehensive assessment of other drugs being taken, consult pharmacists when necessary to adjust their drug programmes, or choose immunosuppressants that interact less with existing drugs, such as hydroxychlorine, which interact relatively less with most common drugs, and give less consideration to the interaction of the drug in use.
Reference to treatment response and drug dependence
If the patient has previously used an immunosuppressant, and the treatment is more effective and resistant, the continued use of the drug may be given priority at the stage of relapse or subsequent maintenance. Conversely, if there has been a serious adverse response to the use of a drug, such as a severe bone marrow inhibition following the use of sulfur, then the re-selection of immunosuppressants should avoid such drugs and replace them with other appropriate alternatives.
From a sexual point of view, some drugs are easy to take, such as hydroxin, which is usually taken once or twice a day and is relatively easy for patients to remember and adhere to the routine; and cyclophosphate-like intravenous shock treatment, which requires regular infusion to the hospital, may be more appropriate for patients whose place of residence is remote from the hospital, inaccessible or less observant, to opt for orally convenient immunosuppressants, provided that the purpose of controlling the condition, such as oral phenolate, is achieved, which helps to increase the patient ‘ s dependence on long-term regular medication and to guarantee treatment effectiveness.
In sum, the selection of self-appropriate immunosuppressants by systematic erythalamus patients is a process that combines multiple factors, requires the identification of the best possible drug programme, under the guidance of a specialist in rheumatism, taking into account his/her own circumstances, and is periodically reviewed, closely monitored in the course of the use of the drug, with a view to adjusting the treatment strategy in a timely manner.
